E Fund Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

E Fund Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-64,520	Closed	-$271K	–	343
2023 Q1	$271K	Sell	64,520 -12,581	-16%	-$65.3K	0.02%	246
2022 Q4	$463K	Buy	77,101 +1,968	+3%	+$10.7K	0.04%	144
2022 Q3	$437K	Buy	75,133 +24,962	+50%	+$156K	0.04%	160
2022 Q2	$300K	Buy	+50,171	New	+$257K	0.03%	231

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

E Fund Management's CTIC Position: Q2 2023 in Review

E Fund Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 64,520 shares — an estimated $271K sold.

E Fund Management first reported a position in CTIC in Q2 2022 and held it in 4 quarters. The position peaked at $463K in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

E Fund Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
E Fund Management sold 64,520 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $271K.
E Fund Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2022 and held it in 4 quarters.
E Fund Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $463K in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on E Fund Management's 13F filing for Q2 2023, filed 11 Aug 2023.